Providing access through evidence
In 2019, Pharmerit joined OPEN Health to create a full service, trusted, innovative partner for HEOR and Medical Affairs.
Looking for support? Get in touch with us
Why Pharmerit and OPEN Health?
Together, we offer a truly comprehensive suite of services to identify and address evidence gaps and deliver world class communications across a wide range of media. Combined with our broad scope of therapeutic expertise, we produce results and solutions that are of the highest quality.
What We Do
Our multidisciplinary teams work across 4 Centers of Excellence to communicate a product’s value.
Modeling and Meta-Analysis
Developing tools to inform policy decision makers about the clinical and health economic consequences of health technologies
Real-World Evidence and Data Analytics
Designing studies using data from patient medical records, insurance claims, and clinical trials.
Patient-Centered Outcomes
Developing, refining, and analyzing outcomes, quantifying values, and optimizing study designs to highlight the patient voice.
Strategic Market Access
Communicating evidence regarding unmet needs and the benefits and costs of treatment innovations to ensure market access.
Latest News and Views
OPEN VIE – Finalists at the Communiqué Awards 2020
We are delighted to see that OPEN VIE is a Finalist, not once but twice, in this year's Communiqué Awards!
Today is Juneteenth and we celebrate it every year. But this year isn’t like most years.
Today is Juneteenth and we celebrate it every year. But this year isn’t like most years.
Jeff Anderson joins OPEN Health as European Lead for OPEN VIE and Pharmerit
Jeff Anderson appointed as European Lead for OPEN VIE and Pharmerit Europe
Solving pharma’s biggest challenges
People are at the heart of our business. Without our incredibly talented people, we couldn’t offer our clients the world-class service they have come to expect.
We know how important it is to support, develop, reward and encourage our team. And that’s just part of what makes Pharmerit – an OPEN Health Company a great place to work.
Latest News
A QTWiST Analysis of Glasdegib Plus Low‐Dose Cytarabine Versus Low‐Dose Cytarabine as Initial Therapy for Acute Myeloid Leukemia in Patients Who Are Not Considered Candidates for Intensive Chemotherapy
A Quality‐Adjusted Survival Time Without Symptoms or Toxicities
Epidemiologic, Humanistic and Economic Burden of Hepatocellular Carcinoma in the USA: A Systematic Literature Review
Epidemiologic, Humanistic and Economic Burden of Hepatocellular Carcinoma in
Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular Degeneration – A Systematic Review of the Impact of Anti-VEGF on Patient Outcomes and Healthcare Systems
Anti-Vascular Endothelial Growth Factor in Neovascular Age-Related Macular
